ArticleActa pharmaceutica Sinica. B2025
A dual-targeting peptide-drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer.
Kun Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it